Teva Pharmaceutical Industries Ltd, ADR (TEVA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

5 BAZEL ST PETACH TIKVA, ISRAEL 49131

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Tevas active pharmaceutical ingredient (API) business provides vertical integration to Tevas own pharmaceutical production. The Companys global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States.

Data as of 2020-08-09
Market Cap13.062 Billion Shares Outstanding1.096 Billion Avg 30-day Volume8.305 Million
P/E Ratio1192.0 Dividend Yield EPS-3.49
Price/Sales0.792 Price cash flow ratio9.1 Price free cash flow ratio43.3
Book Value12.64 Price to Tangible Book-0.63 Alpha-0.03
Short Interest Ratio2.42 % Short Interest to Float2.0 R-squared0.326659
BETA2.34813 52-week High/Low13.76 / 6.07 Stddev0.172763
View SEC Filings from TEVA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 6 7 (0.46%)
13F Filers holding this stock: 438 86 (5.63%)
Aggregate 13F shares on 03/31/2020: 526.598 Million 89.453 Million
Aggregate 13F shares on 12/31/2019: 587.147 Million 157.152 Million
Percent change: -10.31% -43.08%
Funds creating new positions: 84 25
Funds Adding to an existing position: 151 28
Funds closing out their position: 66 15
Funds reducing their position: 112 25
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TEVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TEVA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VERGIS JANET S.

  • Director
12,941 2020-08-04 2

BARER SOL J

  • Director
0 2020-06-18 3

SULZBERGER GABRIELLE

  • Director
2,328 2020-06-16 0

CRANE ROSEMARY A

  • Director
28,413 2020-06-11 2

ELSTEIN AMIR

  • Director
2,016,269 2020-06-11 2

HALFON JEAN MICHEL

  • Director
22,563 2020-06-11 2

LIEBERMAN GERALD M

  • Director
27,963 2020-06-11 2

MIGNONE ROBERTO

  • Director
1,517,621 2020-06-11 2

NISEN PERRY

  • Director
17,621 2020-06-11 2

PERES NECHEMIA JACOB

  • Director
17,621 2020-06-11 2

SATCHI-FAINARO RONIT

  • Director
17,621 2020-06-11 2

GOLDBERG MURRAY A

  • Director
36,050 2020-05-18 0

DANIELL RICHARD EXEC. VP, EUROPEAN COMMERCIAL

  • Officer
10,400 2020-03-17 6

DETHLEFS SVEN EVP GLOBAL MARKETING&PORTFOLIO

  • Officer
20,639 2020-03-17 5

FRIDRIKSDOTTIR HAFRUN EXECUTIVE VP, GLOBAL R&D

  • Officer
45,561 2020-03-17 7

GRIFFIN DEBORAH A CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-03-17 5

NAZZI GIANFRANCO EVP, INTERNATIONAL MARKETS

  • Officer
19,844 2020-03-17 5

O'GRADY BRENDAN P. EVP, NORTH AMERICA COMMERCIAL

  • Officer
14,868 2020-03-17 5

STARK DAVID MATTHEW EXEC. VP CHIEF LEGAL OFFICER

  • Officer
2,974 2020-03-17 5

SCHULTZ KARE PRESIDENT AND CEO

  • Officer
  • Director
0 2020-02-28 4

SABAG MARK SEE "REMARKS" BELOW

  • Officer
0 2020-02-28 4

DRAPE ERIC EXECUTIVE VP GLOBAL OPERATIONS

  • Officer
0 2020-02-28 6

KALIF ELIYAHU SHARON EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2020-02-28 3

MCCLELLAN MICHAEL JAMES EVP, CHIEF FINANCIAL OFFICER

  • Officer
15,898 2019-11-05 2

DE NOTARISTEFANI CARLO EXECUTIVE VP GLOBAL OPERATIONS

  • Officer
33,589 2019-05-18 0

CODNER IRIS BECK EVP GLOBAL BRAND&COMMUNICATION

  • Officer
0 2019-03-04 0

SUESSKIND DAN S

  • Director
318,836 2018-01-19 0

MAOR GALIA

  • Director
0 2018-01-01 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments